JP2025004002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025004002A5 JP2025004002A5 JP2024159834A JP2024159834A JP2025004002A5 JP 2025004002 A5 JP2025004002 A5 JP 2025004002A5 JP 2024159834 A JP2024159834 A JP 2024159834A JP 2024159834 A JP2024159834 A JP 2024159834A JP 2025004002 A5 JP2025004002 A5 JP 2025004002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- variant
- terminus
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 claims 20
- 101150055528 SPAM1 gene Proteins 0.000 claims 20
- 125000000539 amino acid group Chemical group 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 238000012217 deletion Methods 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 238000003259 recombinant expression Methods 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- -1 T475 Substances 0.000 claims 2
- 239000003996 polyglycerol polyricinoleate Substances 0.000 claims 2
- 239000001957 sucroglyceride Substances 0.000 claims 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0086308 | 2018-07-25 | ||
| KR20180086308 | 2018-07-25 | ||
| KR20190029758 | 2019-03-15 | ||
| KR10-2019-0029758 | 2019-03-15 | ||
| PCT/KR2019/009215 WO2020022791A1 (ko) | 2018-07-25 | 2019-07-25 | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| JP2020500863A JP7204729B2 (ja) | 2018-07-25 | 2019-07-25 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2022211105A JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211105A Division JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025004002A JP2025004002A (ja) | 2025-01-14 |
| JP2025004002A5 true JP2025004002A5 (enExample) | 2025-03-19 |
Family
ID=69182377
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500863A Active JP7204729B2 (ja) | 2018-07-25 | 2019-07-25 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2022211105A Pending JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2024159834A Pending JP2025004002A (ja) | 2018-07-25 | 2024-09-17 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500863A Active JP7204729B2 (ja) | 2018-07-25 | 2019-07-25 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2022211105A Pending JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12371683B2 (enExample) |
| EP (1) | EP3636752A4 (enExample) |
| JP (3) | JP7204729B2 (enExample) |
| KR (3) | KR102151388B1 (enExample) |
| CN (5) | CN111971387A (enExample) |
| AU (2) | AU2019311658B2 (enExample) |
| BR (1) | BR112020019041A2 (enExample) |
| CA (1) | CA3093885A1 (enExample) |
| MX (1) | MX2020009824A (enExample) |
| RU (1) | RU2766680C1 (enExample) |
| WO (1) | WO2020022791A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| BR112014016195A2 (pt) | 2011-12-30 | 2020-10-27 | Halozyme, Inc. | variantes de polipeptídio ph20, formulações e usos das mesmas |
| JP7204729B2 (ja) | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| CR20210489A (es) * | 2019-03-25 | 2021-12-07 | Alteogen Inc | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento |
| CN113840921A (zh) | 2020-01-23 | 2021-12-24 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| CN115776909A (zh) | 2020-07-17 | 2023-03-10 | 美国杰龙生物医药公司 | 皮下端粒酶抑制剂组合物及其使用方法 |
| CN120738156A (zh) * | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| EP4217394A1 (en) * | 2020-09-24 | 2023-08-02 | Merck Sharp & Dohme LLC | Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| TW202305009A (zh) | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| CN115671267A (zh) | 2021-07-23 | 2023-02-03 | 上海宝济药业有限公司 | 一种皮下抗生素药物组合物 |
| EP4380618A2 (en) | 2021-08-02 | 2024-06-12 | argenx BV | Subcutaneous unit dosage forms |
| EP4401758A1 (en) | 2021-09-14 | 2024-07-24 | Takeda Pharmaceutical Company Limited | Facilitated delivery of concentrated antibody formulations using hyaluronidase |
| AU2022376750A1 (en) * | 2021-10-29 | 2024-05-16 | Alteogen Inc. | Pharmaceutical composition comprising human hyaluronidase ph20 and drug |
| EP4469586A1 (en) | 2022-03-01 | 2024-12-04 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| CN114573715A (zh) * | 2022-03-14 | 2022-06-03 | 江苏雅酶医药科技有限公司 | 一种重组长效人透明质酸酶及其生产方法和应用 |
| KR20230150203A (ko) | 2022-04-20 | 2023-10-30 | 주식회사 알토스바이오로직스 | 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| KR102774438B1 (ko) * | 2022-06-08 | 2025-02-27 | (주)한국비엠아이 | 히알루로니다제 폴리펩티드 및 이의 용도 |
| CA3240340A1 (en) | 2022-06-22 | 2023-12-28 | Soon Jae Park | N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof |
| US20250345403A1 (en) * | 2022-06-29 | 2025-11-13 | Odysgen Inc. | Hyaluronidase hyal1 variant exhibiting activity in neutral ph |
| KR102621518B1 (ko) * | 2022-06-29 | 2024-01-10 | 주식회사 오디스젠 | 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체 |
| EP4562049A1 (en) * | 2022-07-28 | 2025-06-04 | Merck Sharp & Dohme LLC | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and rhuph20 or variants or fragments thereof |
| WO2024025986A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof |
| KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
| WO2024138188A1 (en) | 2022-12-22 | 2024-06-27 | Halozyme, Inc. | Hyaluronidase enzyme formulations for high volume administration |
| CN120936711A (zh) * | 2023-03-23 | 2025-11-11 | 阿特根公司 | 新型透明质酸酶变体及包括其的药物组合物 |
| KR20250086876A (ko) * | 2023-12-06 | 2025-06-16 | (주)한국비엠아이 | 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물 |
| WO2025136032A1 (ko) * | 2023-12-21 | 2025-06-26 | 주식회사 오디스젠 | 개선된 특성을 갖는 히알루로니다제 hyal2 변이체 |
| KR102875495B1 (ko) * | 2023-12-28 | 2025-10-27 | 주식회사 오디스젠 | 히알루로니다제 Hyal1 변이체 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
| US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| CA2517145C (en) * | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| KR20080082628A (ko) | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 수용체 및 리간드 이소형태의 제조 방법 |
| WO2009037566A2 (en) | 2007-06-19 | 2009-03-26 | Uvarkina Tamara P | Hyaluronidase and method of use thereof |
| ITMI20072225A1 (it) | 2007-11-23 | 2009-05-24 | Luso Farmaco Inst | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
| CN106906196A (zh) | 2008-03-06 | 2017-06-30 | 哈洛齐梅公司 | 可溶性透明质酸酶的大规模生产 |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| JP2011519361A (ja) * | 2008-04-14 | 2011-07-07 | ハロザイム インコーポレイテッド | 修飾されたヒアルロニダーゼおよびヒアルロナン関連疾患および状態の治療における使用 |
| ES2573462T3 (es) | 2008-12-09 | 2016-06-08 | Halozyme, Inc. | Polipéptidos de PH20 soluble extendida y usos de los mismos |
| ES2724588T3 (es) | 2008-12-09 | 2019-09-12 | Halozyme Inc | Polipéptidos de PH20 soluble extendida y usos de los mismos |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US20100305500A1 (en) | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| KR20140043438A (ko) | 2011-06-17 | 2014-04-09 | 할로자임, 아이엔씨 | 히알루로난 분해 효소의 안정한 제형 |
| BR112014016195A2 (pt) * | 2011-12-30 | 2020-10-27 | Halozyme, Inc. | variantes de polipeptídio ph20, formulações e usos das mesmas |
| CN103173474B (zh) | 2013-03-27 | 2014-08-27 | 广州白云山拜迪生物医药有限公司 | 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列 |
| JP6357363B2 (ja) | 2013-06-26 | 2018-07-11 | 株式会社半導体エネルギー研究所 | 記憶装置 |
| TW201534726A (zh) * | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| WO2015071366A1 (en) | 2013-11-13 | 2015-05-21 | Tillotts Pharma Ag | Multi-particulate drug delivery system |
| KR102630750B1 (ko) | 2013-12-17 | 2024-01-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
| US20170218382A1 (en) | 2014-07-31 | 2017-08-03 | National University Corporation Kobe University | Secretion Signal Peptide, And Protein Secretory Production And Cell Surface Display Using Said Secretion Signal Peptide |
| HRP20190881T1 (hr) | 2014-08-28 | 2019-07-12 | Halozyme, Inc. | Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke |
| EP3207130B1 (en) | 2014-10-14 | 2019-08-07 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| CN104745553B (zh) | 2015-03-27 | 2017-11-28 | 杭州北斗生物技术有限公司 | 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法 |
| CA2896038C (en) | 2015-07-03 | 2022-08-09 | Glycobiosciences Inc. | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof |
| US9995753B2 (en) | 2015-09-25 | 2018-06-12 | Merck Sharp & Dohme Corp. | Anti-pembrolizumab antibodies |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| CN105567606B (zh) | 2016-03-02 | 2019-03-19 | 青岛海洋生物医药研究院股份有限公司 | 一种球形节杆菌及其产生的透明质酸酶 |
| WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| KR20250036268A (ko) | 2017-03-31 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| JP7204729B2 (ja) | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| BR112021016398A2 (pt) | 2019-02-22 | 2021-11-23 | Memorial Sloan Kettering Cancer Center | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer |
| CR20210489A (es) | 2019-03-25 | 2021-12-07 | Alteogen Inc | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento |
| JP2020197994A (ja) | 2019-06-04 | 2020-12-10 | 東芝テック株式会社 | 情報処理装置及びその制御プログラム |
| CN113840921A (zh) | 2020-01-23 | 2021-12-24 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| CN120738156A (zh) | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| EP4217394A1 (en) | 2020-09-24 | 2023-08-02 | Merck Sharp & Dohme LLC | Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof |
| AU2022376750A1 (en) | 2021-10-29 | 2024-05-16 | Alteogen Inc. | Pharmaceutical composition comprising human hyaluronidase ph20 and drug |
-
2019
- 2019-07-25 JP JP2020500863A patent/JP7204729B2/ja active Active
- 2019-07-25 RU RU2020130922A patent/RU2766680C1/ru active
- 2019-07-25 US US16/628,258 patent/US12371683B2/en active Active
- 2019-07-25 CN CN201980023392.4A patent/CN111971387A/zh active Pending
- 2019-07-25 BR BR112020019041-1A patent/BR112020019041A2/pt unknown
- 2019-07-25 KR KR1020207002955A patent/KR102151388B1/ko active Active
- 2019-07-25 CN CN202411133487.0A patent/CN118755703A/zh active Pending
- 2019-07-25 WO PCT/KR2019/009215 patent/WO2020022791A1/ko not_active Ceased
- 2019-07-25 AU AU2019311658A patent/AU2019311658B2/en active Active
- 2019-07-25 CN CN202411131388.9A patent/CN118773171A/zh active Pending
- 2019-07-25 CA CA3093885A patent/CA3093885A1/en active Pending
- 2019-07-25 KR KR1020257002900A patent/KR20250021616A/ko active Pending
- 2019-07-25 KR KR1020207024813A patent/KR20210023798A/ko active Pending
- 2019-07-25 CN CN202411131157.8A patent/CN118853631A/zh active Pending
- 2019-07-25 MX MX2020009824A patent/MX2020009824A/es unknown
- 2019-07-25 EP EP19827585.1A patent/EP3636752A4/en active Pending
- 2019-07-25 CN CN202411127100.0A patent/CN118792283A/zh active Pending
-
2022
- 2022-12-28 JP JP2022211105A patent/JP2023052142A/ja active Pending
-
2023
- 2023-01-20 AU AU2023200324A patent/AU2023200324B9/en active Active
-
2024
- 2024-09-17 JP JP2024159834A patent/JP2025004002A/ja active Pending
-
2025
- 2025-06-06 US US19/231,008 patent/US20250368976A1/en active Pending